Skip to main content
Category

Commentary

What Will Medicare Really Cost?

By Commentary No Comments

When the Congressional Budget Office and the Board of Trustees of the Medicare trust funds make projections about future Medicare expenditures and revenues, they are required to utilize current law, even when everyone knows it doesn’t reflect likely reality. A memo from the Office of the Actuary presents an alternative, probably more accurate, set of Medicare projections.

Read More

2012 Potpourri XX

By Commentary No Comments

Our Potpourri resumes, with information on consumer trust of insurers and providers, consumer use of online health information, price transparency in health care, imaging rates in integrated health care systems and effectiveness of telephonic depression therapy.

Read More

E-Prescribing Status Report

By Commentary No Comments

The latest annual report on e-prescribing from SureScripts reveals continued rapid growth. The report also details benefits which appear to flow from greater use of electronic prescribing and opportunities to use the network created by SureScripts to address information sharing in other health care sectors.

Read More

PWC 2013 Cost Projections

By Commentary No Comments

PWC’s Health Research Institute is projecting that overall medical cost trend for employment-based health care coverage will be around 7.5% for 2013, which is identical to the number it currently estimates for 2012 and close to the 2011 and 2010 actuals.

Read More

2012 Potpourri XIX

By Commentary No Comments

Summer is heating up and our Potpourri is smoking too, with nuggets on a silly provision in the final MLR rule; research on causes of readmissions, some within hospital control, some not; why are some hospitals more costly in treating heart failure than others and an unintended consequence of a change in dialysis drug reimbursement.

Read More

Care Management Kills?

By Commentary No Comments

Research reported in the Annals of Internal Medicine finds that a comprehensive care management program for chronic obstructive pulmonary disease had excess mortality, to the point that the trial was stopped early. It seems unlikely that this was actually due to the trial.

Read More